phrykt

Biomarin Pharmaceutical Inc (BMRN): who owns it and who trades it

As of Nov 16, 2026, BMRN insiders reported 5 open-market sales worth $4.3M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was George Eric Davis (Vice president), with $2.8M. 6 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Biomarin Pharmaceutical

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns BMRN

562 funds and institutions reported BMRN shares worth $11.3B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 10.6%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

BlackRock, Inc.10.6%
Dodge & Cox7.7%
Primecap Management Co7.3%
Vanguard Capital Management LLC4.5%
Vanguard Portfolio Management LLC4.5%
Norges Bank4.2%
State Street Corp4.0%
Viking Global Investors LP3.9%
Vestal Point Capital, LP3.1%
AQR Capital Management LLC2.9%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.20.45M10.58%$1.2B+3%
Dodge & Cox14.84M7.68%$849M+2%
Primecap Management Co14.19M7.34%$812MNo change
Vanguard Capital Management LLC8.74M4.52%$500M+1%
Vanguard Portfolio Management LLC8.65M4.47%$495M+4%
Norges Bank8.21M4.25%$470M–
State Street Corp7.80M4.04%$446M+7%
Viking Global Investors LP7.62M3.94%$436M+8%
Vestal Point Capital, LP6.03M3.12%$345M+69%
AQR Capital Management LLC5.70M2.95%$323M-26%
FMR LLC (Fidelity)4.82M2.50%$276M+35%
Dimensional Fund Advisors LP4.08M2.11%$233M+7%
Geode Capital Management, LLC3.91M2.02%$224M+2%
Assenagon Asset Management S.A.3.52M1.82%$202M+83%
Capital Research Global Investors3.50M1.81%$201M+0%
Deep Track Capital, LP3.31M1.71%$189M+188%
Millennium Management LLC2.07M1.07%$119M-31%
Charles Schwab Investment Management Inc1.62M0.84%$92.5M+2%
Sixth Street Partners Management Company, L.P.1.62M0.84%$92.5M–
First Trust Advisors LP1.61M0.83%$91.9M-4%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, BMRN insiders reported $0 of open-market purchases and $4.3M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$4.3M
5 trades, 3 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Sep 2, 2026
Filed Sep 3, 2026

Purchases and sales by month

$2M$2MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 2, 2026George Eric DavisVice presidentSale17,557$66.28$1.2MForm 4
May 7, 2026Gregory R FribergVice presidentSale3,281$53.85$177KForm 4
Mar 11, 2026Charles Greg GuyerVice presidentSale16,486$60.46$997KForm 4
Feb 26, 2026Gregory R FribergVice presidentSale6,326$60.38$382KForm 4
Feb 26, 2026George Eric DavisVice presidentSale26,061$61.36$1.6MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
George Eric DavisEVP, Chief Legal Officer–$2.8MSep 2, 2026
Charles Greg GuyerEVP, Chief Technical Officer–$997KMar 11, 2026
Gregory R FribergEVP, Chief R&D Officer–$559KMay 7, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

BMRN short interest

Moderate short interest. 7.3% of BMRN shares are sold short: about 1 share in 14. Over the last 12 reports the number of shares short went up 24%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 14.12M BMRN shares were sold short, 7.3% of the shares outstanding, up 17.2% from the report before. At the average daily volume of 2.45M shares, buying them all back would take about 5.8 trading days (days to cover).

Shares short, % of all shares

7.29%May 15Oct 307.75%

Days to cover

5.8May 15Oct 3011.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202614.12M7.29%+17%2.45M5.8
Oct 15, 202612.05M6.23%+5%2.46M4.9
Sep 30, 202611.52M5.95%+14%2.09M5.5
Sep 15, 202610.08M5.21%+2%1.82M5.5
Aug 31, 20269.88M5.10%-3%1.71M5.8
Aug 14, 202610.20M5.27%-18%2.77M3.7
Jul 31, 202612.50M6.46%-13%1.68M7.4
Jul 15, 202614.32M7.41%+3%1.41M10.2
Jun 30, 202613.91M7.20%+11%2.30M6.0
Jun 15, 202612.52M6.48%+8%2.07M6.1
May 29, 202611.61M6.00%+2%2.92M4.0
May 15, 202611.36M5.88%+5%2.10M5.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Biomarin Pharmaceutical company events

Biomarin Pharmaceutical filed 23 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 2, 2026.

  1. Nov 2, 2026ResultsReleased financial results. Filing
  2. Oct 6, 2026ResultsReleased financial results. Filing
  3. Sep 30, 2026AgreementBioMarin Pharmaceutical Inc. (BioMarin) entered into a Settlement and License Agreement (the Agreement) with Ascendis Pharma A/S (Ascendis). Filing
  4. Sep 15, 2026AnnouncementBioMarin Pharmaceutical Inc. (BioMarin) announced its decision to discontinue development of VOXZOGO for children with Noonan syndrome. Filing
  5. Sep 14, 2026LeadershipThe Board of Directors (the Board) of BioMarin Pharmaceutical Inc. (the Company) increased the size of the Board from ten to eleven members and appointed Robert Plenge, M.D., Ph.D., to the Board, to be effective September 10, 2026 (the Appointment Date). Filing
  6. Sep 1, 2026AnnouncementAs previously reported in the Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on August 18, 2026, BioMarin Pharmaceutical Inc., a Delaware corporation, entered into a Share Purchase Agreement with (i) Alesta Therapeutics B.V., a Dutch private limited liability… Filing
  7. Aug 31, 2026AgreementBioMarin Pharmaceutical Inc. entered into a binding term sheet with Ascendis Pharma A/S that sets forth the terms and conditions for a global settlement and license agreement that resolves all pending proceedings relating to the BioMarin Patent Rights (as defined below). Filing
  8. Aug 18, 2026AgreementBioMarin Pharmaceutical Inc., a Delaware corporation, entered into a Share Purchase Agreement with (i) Alesta Therapeutics B.V., a Dutch private limited liability company ( besloten vennootschap met beperkte aansprakelijkheid ), (ii) each of the holders of shares of Alesta identified on Schedule… Filing
  9. Aug 6, 2026ResultsReleased financial results. Filing
  10. Jul 13, 2026AnnouncementAmended an earlier report. Made another announcement. Filing
  11. Jun 4, 2026LeadershipBioMarin Pharmaceutical Inc. (BioMarin or the Company) held its 2026 Annual Meeting of Stockholders (the Annual Meeting). Filing
  12. May 4, 2026ResultsReleased financial results. Filing
  13. Apr 27, 2026DealThe information set forth in the “Introductory Note” above is incorporated into this Item 2.01 by reference. Filing
  14. Apr 23, 2026AnnouncementAs previously disclosed, on December 19, 2025, BioMarin Pharmaceutical Inc. and Lynx Merger Sub 1, Inc., a wholly owned subsidiary of BioMarin entered into an Agreement and Plan of Merger with Amicus Therapeutics, Inc., providing for the merger of Merger Sub with and into Amicus, with Amicus… Filing
  15. Mar 16, 2026AnnouncementBioMarin Pharmaceutical Inc. announced its decision to discontinue dosing and enrollment in its Phase 2 trials for VOXZOGO in Turner Syndrome, SHOX-deficiency and Aggrecan (ACAN)-deficiency following the occurrence of several slipped capital femoral epiphysis (SCFE) events in two ongoing… Filing
  16. Feb 23, 2026ResultsReleased financial results. Filing
  17. Feb 12, 2026AgreementBioMarin Pharmaceutical Inc. (BioMarin or the company) completed its previously-announced private placement of $850 million of 5.500% Senior Notes due 2026 (the Notes) to several investment banks acting as initial purchasers who subsequently resold the Notes to qualified institutional buyers as… Filing
  18. Jan 29, 2026AnnouncementShared information with investors. Filing
  19. Jan 26, 2026AnnouncementSupplemental Information In connection with the Offering, BioMarin distributed a preliminary offering memorandum to prospective investors, which memorandum includes a description of risks related to the Acquisition. Filing
  20. Jan 12, 2026ResultsReleased financial results. Filing
  21. Dec 22, 2025AnnouncementBioMarin Pharmaceutical Inc. announced its decision to discontinue development of BMN 349, an oral therapeutic for Alpha-1 antitrypsin deficiency (AATD)-associated liver disease. Filing
  22. Dec 19, 2025AgreementBioMarin Pharmaceutical Inc., a Delaware corporation, entered into an Agreement and Plan of Merger with Amicus Therapeutics, Inc., and Lynx Merger Sub 1, Inc., a Delaware corporation and wholly owned subsidiary of BioMarin, providing for the merger of Merger Sub with and into Amicus, with Amicus… Filing
  23. Dec 17, 2025LeadershipBioMarin Pharmaceutical Inc. (BioMarin) announced the appointment of Rashmi Ramchandani as BioMarin’s Vice President, Chief Accounting Officer, effective January 19, 2026. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Biomarin Pharmaceutical financials

Famous investors that hold BMRN

6 of the 50 well-known investors we track reported holding BMRN in their latest 13F filing. The largest position is Andreas Halvorsen's, worth $430M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Andreas Halvorsen · Viking Global InvestorsQ3 20267.17M$430M1.3%-6%
Ken Griffin · Citadel AdvisorsQ3 20262.18M$131M0.1%+95%
Israel Englander · Millennium ManagementQ3 20261.22M$73.1M0.1%-41%
Steve Cohen · Point72 Asset ManagementQ3 2026878,931$52.7M0.1%New
Jim Simons · Renaissance TechnologiesQ3 2026727,771$43.7M0.1%+61%
Lee Ainslie · Maverick CapitalQ3 20264,088$245K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named BMRN in the last 120 days.

FiledHolderFormStake
Nov 4, 2026BlackRock, Inc.13G/A10.0%
Nov 4, 2026BlackRock, Inc.13G/A10.0%

Questions about Biomarin Pharmaceutical Inc (BMRN) stock

Who owns the most BMRN stock?

The largest reported owner of Biomarin Pharmaceutical Inc (BMRN) is BlackRock, Inc., with 10.6% of the company. In total, 562 funds and institutions reported holding BMRN at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are BMRN insiders buying or selling?

In the last 12 months, BMRN insiders reported no open-market purchases and 5 sales worth $4.3M. The latest trade was on Sep 2, 2026. See every trade.

What is the short interest in BMRN?

As of Oct 30, 2026, 14.12M BMRN shares were sold short, 7.3% of the shares outstanding, up 17.2% from the report before. At the average daily volume of 2.45M shares, buying them all back would take about 5.8 trading days (days to cover). See the history.

Which famous investors hold BMRN?

6 of the 50 well-known investors we track reported BMRN in their latest 13F filing, including Andreas Halvorsen, Ken Griffin, Israel Englander. The largest position is worth $430M. See all holders.

Executive pay

Biomarin Pharmaceutical's chief executive was paid a total of $21.9M for the year ended Dec 31, 2025. In the last 12 months, Biomarin Pharmaceutical's executives and directors bought no stock on the open market and sold $4.3M.

Chief executive, total pay$21.9MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$12.2MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$6.4MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.